Research press release


Nature Genetics

Sequencing gallbladder cancer identifies important mutations



今回、Yingbin Liuたちは、57点の胆嚢がん検体を中国人患者から採取し、検体中の遺伝子変異を調べた。その結果、検体の約37%において、重要な細胞増殖・生存経路であるErbBシグナル伝達経路の複数の遺伝子が変異しており、それが予後不良と結びついていることが判明した。さらに、これらの遺伝子が胆嚢がんに及ぼす影響に関する検証が実験室内で行われ、ErbBシグナル伝達経路の遺伝子であるERBB3の変異体と正常なERBB2が同時に活性化している場合に、がん細胞の増殖速度がかなり上昇し、侵襲性の強いがんとの整合性を示した。


The genetic sequence of gallbladder cancer in Chinese patients is reported in a study published online this week in Nature Genetics. The results may lead to the development of new targeted therapies for about one-third of gallbladder cancer patients.

Gallbladder cancer is a rare and often fatal type of cancer that is more common in certain populations, such as East Asians and Northern Indians. In addition, people with gallstones and chronic inflammation are at higher risk for gallbladder cancer.

Yingbin Liu and colleagues studied mutations present in 57 gallbladder cancer samples from Chinese patients. They found that genes in the ErbB signalling pathway-an important pathway in cell growth and survival-impacted nearly 37% of samples and are linked to poor prognosis. Further tests of the effects of these genes in gallbladder cancer cells in the lab showed that when a mutated form of one ErbB pathway gene, ERBB3, was active at the same time as a normal form of another, ERBB2, cells grew much faster; consistent with a more aggressive cancer.

Drugs that inhibit genes in the ErbB pathway have already been developed and are currently being tested in other cancers with similar mutations.

doi: 10.1038/ng.3030


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。